On Thursday,
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF, Forum) provided investors with additional information on its interim data report for the Phase 2b part of the Company’s Phase 2b/3 clinical study of NP-120 (Ifenprodil) for COVID-19. This includes data on endpoints for the study under World Health Organization and the Food and Drug Administration, including Emergency Use Authorization.
For the full news release, click
here.
Earlier this week, the Vancouver, BC-based clinical stage pharmaceutical development and drug repurposing Company reported
positive trending interim data for the Phase 2b part of the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, stated that this interim data has provided AGN with some positive trending information, the team still needs to evaluate the full definitive results and statistics to be presented with the final data set.
“We will be especially interested to see the numbers on the overall time spent on ventilation and rate to ventilation to be reported in the final data set.”
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.